|1||NCT02978625||Suspended||Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers||
||68||All||18 Years and older (Adult, Older Adult)||NCT02978625||NCI-2016-01804
|September 18, 2017||January 1, 2020||January 1, 2020||December 1, 2016||August 6, 2019||
|2||NCT01046487||Completed||Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate||
||26||All||18 Years and older (Adult, Older Adult)||NCT01046487||PALANGI-3 0804||PALANGI3||January 2009||April 2011||February 2012||January 12, 2010||June 7, 2012||
† Study has passed its completion date and status has not been verified in more than two years.